CD56brightCD16- NK cells produce adenosine through a CD38-mediated pathway and act as regulatory cells inhibiting autologous CD4+ T cell proliferation

Journal of Immunology

Volumn 195, Issue 3, 2015, Pages 965-972

  Morandi, Fabio ^a   Horenstein, Alberto L ^b,c   Chillemi, Antonella ^b   Quarona, Valeria ^b   Chiesa, Sabrina ^a   Imperatori, Andrea ^d   Zanellato, Silvia ^d   Mortara, Lorenzo ^d   Gattorno, Marco ^a   Pistoia, Vito ^a   Malavasi, Fabio ^b,c  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^d UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; CD16 ANTIGEN; CD203A ANTIGEN; CD38 ANTIGEN; CD56 ANTIGEN; CD57 ANTIGEN; LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG; 5' NUCLEOTIDASE; ADENOSINE DIPHOSPHATE RIBOSYL CYCLASE; ADP-RIBOSYL CYCLASE 2; APYRASE; CD38 PROTEIN, HUMAN; CD39 ANTIGEN; FC RECEPTOR; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; NCAM1 PROTEIN, HUMAN; NT5E PROTEIN, HUMAN;

ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CELL ASSAY; CELL ISOLATION; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MOLECULAR DYNAMICS; NATURAL KILLER CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SYNOVIAL FLUID; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL PROLIFERATION; CYTOLOGY; GENETICS; IMMUNOLOGY; JUVENILE RHEUMATOID ARTHRITIS; LYMPHOCYTE ACTIVATION; METABOLISM;

5'-NUCLEOTIDASE; ADENOSINE; ADP-RIBOSYL CYCLASE; ANTIGENS, CD; ANTIGENS, CD38; ANTIGENS, CD56; ANTIGENS, CD57; APYRASE; ARTHRITIS, JUVENILE; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; GPI-LINKED PROTEINS; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; RECEPTORS, IGG; SYNOVIAL FLUID;

EID: 84937714187     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1500591     Document Type: Article

References (30)

1. Trinchieri, G., and D. Santoli. 1978. Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis. J. Exp. Med. 147: 1314-1333.
2. Moretta, A., E. Marcenaro, S. Sivori, M. Della Chiesa, M. Vitale, and L. Moretta. 2005. Early liaisons between cells of the innate immune system in inflamed peripheral tissues. Trends Immunol. 26: 668-675.
3. Martín-Fontecha, A., L. L. Thomsen, S. Brett, C. Gerard, M. Lipp, A. Lanzavecchia, and F. Sallusto. 2004. Induced recruitment of NK cells to lymph nodes provides IFN-g for TH1 priming. Nat. Immunol. 5: 1260-1265.
4. Matos, M. E., G. S. Schnier, M. S. Beecher, L. K. Ashman, D. E. William, and M. A. Caligiuri. 1993. Expression of a functional c-kit receptor on a subset of natural killer cells. J. Exp. Med. 178: 1079-1084.
5. Moretta, A., E.Marcenaro, S. Parolini, G. Ferlazzo, and L. Moretta. 2008. NK cells at the interface between innate and adaptive immunity. Cell Death Differ. 15: 226-233.
6. Yu, J., H. C. Mao, M. Wei, T. Hughes, J. Zhang, I. K. Park, S. Liu, S. McClory, G. Marcucci, R. Trotta, and M. A. Caligiuri. 2010. CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets. Blood 115: 274-281.
7. Airas, L., M. Saraste, S. Rinta, I. Elovaara, Y. H. Huang, and H. Wiendl, Finnish Multiple Sclerosis and Pregnancy Study Group. 2008. Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells. Clin. Exp. Immunol. 151: 235-243.
8. Fu, B., X. Li, R. Sun, X. Tong, B. Ling, Z. Tian, and H. Wei. 2013. Natural killer cells promote immune tolerance by regulating inflammatory TH17 cells at the human maternal-fetal interface. Proc. Natl. Acad. Sci. USA 110: E231-E240.
9. Schepis, D., I. Gunnarsson, M. L. Eloranta, J. Lampa, S. H. Jacobson, K. Kärre, and L. Berg. 2009. Increased proportion of CD56bright natural killer cells in active and inactive systemic lupus erythematosus. Immunology 126: 140-146.
10. Vandenbark, A. A., J. Huan, M. Agotsch, D. La Tocha, S. Goelz, H. Offner, S. Lanker, and D. Bourdette. 2009. Interferon-b-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis. J. Neuroimmunol. 215: 125-128.
11. Bielekova, B., M. Catalfamo, S. Reichert-Scrivner, A. Packer, M. Cerna, T. A. Waldmann, H. McFarland, P. A. Henkart, and R. Martin. 2006. Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Ratargeted therapy (daclizumab) in multiple sclerosis. Proc. Natl. Acad. Sci. USA 103: 5941-5946.
12. Laroni, A., R. Gandhi, V. Beynon, and H. L. Weiner. 2011. IL-27 imparts immunoregulatory function to human NK cell subsets. PLoS ONE 6: e26173.
13. Huang, S., S. Apasov, M. Koshiba, and M. Sitkovsky. 1997. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood 90: 1600-1610.
14. Schiedel, A. C., S. K. Lacher, C. Linnemann, P. A. Knolle, and C. E. Müller. 2013. Antiproliferative effects of selective adenosine receptor agonists and antagonists on human lymphocytes: evidence for receptor-independent mechanisms. Purinergic Signal. 9: 351-365.
15. Takahashi, H. K., H. Iwagaki, R. Hamano, T. Kanke, K. Liu, H. Sadamori, T. Yagi, T. Yoshino, T. Sendo, N. Tanaka, and M. Nishibori. 2007. Effect of adenosine receptor subtypes stimulation on mixed lymphocyte reaction. Eur. J. Pharmacol. 564: 204-210.
16. Sakata, N., H. Kawasome, N. Terada, G. L. Johnson, and E. W. Gelfand. 2000. CD40 and adenosine A2 receptor agonist-cyclic adenosine monophosphate rescue B-cell antigen receptor-induced apoptosis through independent pathways and converge to prevent caspase activation. J. Allergy Clin. Immunol. 105: 522-531.
17. Napieralski, R., B. Kempkes, and W. Gutensohn. 2003. Evidence for coordinated induction and repression of ecto-59-nucleotidase (CD73) and the A2a adenosine receptor in a human B cell line. Biol. Chem. 384: 483-487.
18. Rickles, R. J., L. T. Pierce, T. P. Giordano, III, W. F. Tam, D. W. McMillin, J. Delmore, J. P. Laubach, A. A. Borisy, P. G. Richardson, and M. S. Lee. 2010. Adenosine A2A receptor agonists and PDE inhibitors: A synergistic multitarget mechanism discovered through systematic combination screening in B-cell malignancies. Blood 116: 593-602.
19. Jeffe, F., K. A. Stegmann, F. Broelsch, M. P. Manns, M. Cornberg, and H. Wedemeyer. 2009. Adenosine and IFN-A synergistically increase IFN-g production of human NK cells. J. Leukoc. Biol. 85: 452-461.
20. Wallace, K. L., and J. Linden. 2010. Adenosine A2A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease. Blood 116: 5010-5020.
21. Häusler, S. F., I. Montalbán del Barrio, J. Strohschein, P. Anoop Chandran, J. B. Engel, A. Hönig, M. Ossadnik, E. Horn, B. Fischer, M. Krockenberger, et al. 2011. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity. Cancer Immunol. Immunother. 60: 1405-1418.
22. Malavasi, F., S. Deaglio, E. Ferrero, A. Funaro, J. Sancho, C. M. Ausiello, E. Ortolan, T. Vaisitti, M. Zubiaur, G. Fedele, et al. 2006. CD38 and CD157 as receptors of the immune system: a bridge between innate and adaptive immunity. Mol. Med. 12: 334-341.
23. Menzaghi, C., R. Di Paola, G. Baj, A. Funaro, A. Arnulfo, T. Ercolino, N. Surico, F. Malavasi, and V. Trischitta. 2003. Insulin modulates PC-1 processing and recruitment in cultured human cells. Am. J. Physiol. Endocrinol. Metab. 284: E514-E520.
24. Serra, S., A. L. Horenstein, T. Vaisitti, D. Brusa, D. Rossi, L. Laurenti, G. D'Arena, M. Coscia, C. Tripodo, G. Inghirami, et al. 2011. CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood 118: 6141-6152.
25. Petty, R. E., T. R. Southwood, J. Baum, E. Bhettay, D. N. Glass, P. Manners, J. Maldonado-Cocco, M. Suarez-Almazor, J. Orozco-Alcala, and A. M. Prieur. 1998. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J. Rheumatol. 25: 1991-1994.
26. Cecati, M., M. Emanuelli, S. R. Giannubilo, V. Quarona, R. Senetta, F. Malavasi, A. L. Tranquilli, and F. Saccucci. 2013. Contribution of adenosine-producing ectoenzymes to the mechanisms underlying the mitigation of maternal-fetal conflicts. J. Biol. Regul. Homeost. Agents 27: 519-529.
27. Horenstein, A. L., A. Chillemi, G. Zaccarello, S. Bruzzone, V. Quarona, A. Zito, S. Serra, and F. Malavasi. 2013. A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes. OncoImmunology 2: e26246.
28. Deaglio, S., K. M. Dwyer, W. Gao, D. Friedman, A. Usheva, A. Erat, J. F. Chen, K. Enjyoji, J. Linden, M. Oukka, et al. 2007. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204: 1257-1265.
29. Chatterjee, D., D. M. Tufa, H. Baehre, R. Hass, R. E. Schmidt, and R. Jacobs. 2014. Natural killer cells acquire CD73 expression upon exposure to mesenchymal stem cells. Blood 123: 594-595.
30. Beavis, P. A., U. Divisekera, C. Paget, M. T. Chow, L. B. John, C. Devaud, K. Dwyer, J. Stagg, M. J. Smyth, and P. K. Darcy. 2013. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc. Natl. Acad. Sci. USA 110: 14711-14716.